Now you see me, now you don't: New approaches to sparing nonmalignant cells from CAR T cell therapies
While new immunotherapies have revolutionized the field of oncology, they have been
limited by their inability to distinguish between cancerous cells and healthy HSPCs. Work by
Casirati et al. 1 and Wellhausen et al. 2 in epitope editing antigens commonly expressed on
AML and HSPCs has unlocked several new targets for immunotherapies.
limited by their inability to distinguish between cancerous cells and healthy HSPCs. Work by
Casirati et al. 1 and Wellhausen et al. 2 in epitope editing antigens commonly expressed on
AML and HSPCs has unlocked several new targets for immunotherapies.
While new immunotherapies have revolutionized the field of oncology, they have been limited by their inability to distinguish between cancerous cells and healthy HSPCs. Work by Casirati et al.1 and Wellhausen et al.2 in epitope editing antigens commonly expressed on AML and HSPCs has unlocked several new targets for immunotherapies.
cell.com
以上显示的是最相近的搜索结果。 查看全部搜索结果